Foreign-Trade Zone (FTZ) 7, Notification of Proposed Production Activity; AbbVie Ltd.; (Pharmaceutical Products); Barceloneta, Puerto Rico, 24386 [2023-08327]
Download as PDF
<![CDATA[
24386
Federal Register / Vol. 88, No. 76 / Thursday, April 20, 2023 / Notices
Estimated Number of Respondents:
300,000.
Estimated Time per Response: Varied,
dependent upon the data collection
method used. The possible response
time to complete a questionnaire or
survey may be 3 minutes or up to 2
hours to participate in an interview or
focus group.
Estimated Total Annual Burden
Hours: 27,725.
Estimated Total Annual Cost to the
Public: Zero.
Respondent’s Obligation: Voluntary.
Affected Public: Collections will be
targeted to the solicitation of opinions
from respondents who have experience
with the program or may have
experience with the program in the near
future. For the purposes of this request,
‘‘customers’’ are individuals,
businesses, and organizations that
interact with a Federal Government
agency or program, either directly or via
a Federal contractor. This could include
individuals or households; businesses
or other for-profit organizations; not-forprofit institutions; State, local or tribal
governments; Federal government; and
Universities.
IV. Request for Comments
ddrumheller on DSK120RN23PROD with NOTICES1
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information will have
practical utility; (b) the accuracy of the
agency’s estimate of the burden
(including hours and cost) of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology.
Comments submitted in response to
this notice will be summarized and/or
included in the request for OMB
approval of this information collection;
they also will become a matter of public
record.
DEPARTMENT OF COMMERCE
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
International Trade Administration
[C–533–874]
[B–29–2023]
Foreign-Trade Zone (FTZ) 7,
Notification of Proposed Production
Activity; AbbVie Ltd.; (Pharmaceutical
Products); Barceloneta, Puerto Rico
AbbVie Ltd., submitted a notification
of proposed production activity to the
FTZ Board (the Board) for its facility in
Barceloneta, Puerto Rico within
Subzone 7I. The notification conforming
to the requirements of the Board’s
regulations (15 CFR 400.22) was
received on April 10, 2023.
Pursuant to 15 CFR 400.14(b), FTZ
production activity would be limited to
the specific foreign-status material(s)/
component(s) and specific finished
product(s) described in the submitted
notification (summarized below) and
subsequently authorized by the Board.
The benefits that may stem from
conducting production activity under
FTZ procedures are explained in the
background section of the Board’s
website—accessible via www.trade.gov/
ftz. The proposed finished product(s)
and material(s)/component(s) would be
added to the production authority that
the Board previously approved for the
operation, as reflected on the Board’s
website.
The proposed finished product is
RINVOQ® (upadacitinib) tablets (dutyfree).
The proposed foreign-status material
is upadacitinib active pharmaceutical
ingredient (duty rate 6.5%).
Public comment is invited from
interested parties. Submissions shall be
addressed to the Board’s Executive
Secretary and sent to: ftz@trade.gov. The
closing period for their receipt is May
30, 2023.
A copy of the notification will be
available for public inspection in the
‘‘Online FTZ Information System’’
section of the Board’s website.
For further information, contact
Christopher Wedderburn at
Chris.Wedderburn@trade.gov.
Sheleen Dumas,
Department PRA Clearance Officer, Office of
the Under Secretary for Economic Affairs,
Commerce Department.
Dated: April 14, 2023.
Elizabeth Whiteman,
Acting Executive Secretary.
[FR Doc. 2023–08301 Filed 4–19–23; 8:45 am]
[FR Doc. 2023–08327 Filed 4–19–23; 8:45 am]
BILLING CODE 3510–DS–P
BILLING CODE 3510–17–P
VerDate Sep<11>2014
20:01 Apr 19, 2023
Jkt 259001
PO 00000
Frm 00005
Fmt 4703
Sfmt 4703
Certain Cold-Drawn Mechanical Tubing
of Carbon and Alloy Steel From India:
Final Results of the Expedited First
Sunset Review of the Countervailing
Duty Order
Enforcement and Compliance,
International Trade Administration,
Department of Commerce.
SUMMARY: The U.S. Department of
Commerce (Commerce) finds that
revocation of the countervailing duty
(CVD) order on certain cold-drawn
mechanical tubing of carbon and alloy
steel (cold-drawn mechanical tubing)
from India would be likely to lead to the
continuation or recurrence of
countervailable subsidies at the levels
indicated in the ‘‘Final Results of Sunset
Review’’ section of this notice.
DATES: Applicable April 20, 2023.
FOR FURTHER INFORMATION CONTACT:
Whitley Herndon, AD/CVD Operations,
Office V, Enforcement and Compliance,
International Trade Administration,
U.S. Department of Commerce, 1401
Constitution Avenue NW, Washington,
DC 20230; telephone: (202) 482–6274.
SUPPLEMENTARY INFORMATION:
AGENCY:
Background
On February 1, 2018, Commerce
published in the Federal Register the
Order on cold-drawn mechanical tubing
from India.1 On January 3, 2023,
Commerce published the notice of
initiation of the first sunset review of
the Order, in accordance with section
751(c) of the Tariff Act of 1930, as
amended (the Act).2 On January 17,
2023, Commerce received a timely
notice of intent to participate from
ArcelorMittal Tubular Products,
Michigan Seamless Tube LLC, PTC
Alliance Corp., Webco Industries, Inc.,
and Zekelman Industries, Inc.
(collectively, the domestic interested
parties).3 The domestic interested
parties claimed interested party status
under section 771(9)(C) of the Act as a
group of domestic producers engaged in
1 See Certain Cold-Drawn Mechanical Tubing of
Carbon and Alloy Steel from the People’s Republic
of China and India: Countervailing Duty Orders, 83
FR 4637 (February 1, 2018) (Order); see also Certain
Cold-Drawn Mechanical Tubing of Carbon and
Alloy Steel from the People’s Republic of China and
India: Countervailing Duty Orders; Correction, 86
FR 30595 (June 9, 2021).
2 See Initiation of Five-Year (Sunset) Reviews, 88
FR 63 (January 3, 2023).
3 See Domestic Interested Parties’ Letter,
‘‘Domestic Interested Parties’ Notice of Intent to
Participate,’’ dated January 17, 2023.
E:\FR\FM\20APN1.SGM
20APN1
]]>Agencies
[Federal Register Volume 88, Number 76 (Thursday, April 20, 2023)]
[Notices]
[Page 24386]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-08327]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-29-2023]
Foreign-Trade Zone (FTZ) 7, Notification of Proposed Production
Activity; AbbVie Ltd.; (Pharmaceutical Products); Barceloneta, Puerto
Rico
AbbVie Ltd., submitted a notification of proposed production
activity to the FTZ Board (the Board) for its facility in Barceloneta,
Puerto Rico within Subzone 7I. The notification conforming to the
requirements of the Board's regulations (15 CFR 400.22) was received on
April 10, 2023.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via www.trade.gov/ftz. The proposed finished
product(s) and material(s)/component(s) would be added to the
production authority that the Board previously approved for the
operation, as reflected on the Board's website.
The proposed finished product is RINVOQ[supreg] (upadacitinib)
tablets (duty-free).
The proposed foreign-status material is upadacitinib active
pharmaceutical ingredient (duty rate 6.5%).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
[email protected]. The closing period for their receipt is May 30, 2023.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Christopher Wedderburn at
[email protected].
Dated: April 14, 2023.
Elizabeth Whiteman,
Acting Executive Secretary.
[FR Doc. 2023-08327 Filed 4-19-23; 8:45 am]
BILLING CODE 3510-DS-P
